Presentation is loading. Please wait.

Presentation is loading. Please wait.

1 One Year Post Exclusivity Adverse Event Review: Ciprofloxacin Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

Published byShon Briggs Modified over 8 years ago

Similar presentations

Presentation on theme: "1 One Year Post Exclusivity Adverse Event Review: Ciprofloxacin Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004."— Presentation transcript:

1 1 One Year Post Exclusivity Adverse Event Review: Ciprofloxacin Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004 J. Harry Gunkel, MD Medical Officer Division of Pediatric Drug Development Center for Drug Evaluation and Research Food and Drug Administration

2 2 Background Drug Information Moiety: Ciloxan ® (ciprofloxacin) Therapeutic Category: Ophthalmic anti-infective Sponsor: Alcon Laboratories, Inc. Indication: Adults and Children > 1 year (solution). Adults and Children > 2 years (ointment): treatment of bacterial conjunctivitis caused by susceptible strains of S. aureus, S. epidermidis, S. pneumoniae, S. viridans, H. flu Original Market Approval: December 31, 1990 Pediatric Exclusivity Granted: January 10, 2003

3 3 Drug Use Trends in Outpatient Settings: Ciprofloxacin Ophthalmic Dispensed prescriptions for Ciloxan decreased from 2.7 to 2.2 million from Feb 2003 through Jan 2004. 1 42.7% of prescriptions were for children 1- 16 yrs. 2 Pediatricians wrote 33% of prescriptions (712,000) from Feb 2003 – Jan 2004. 1 1 IMS Health, National Prescription Audit Plus™, On-line, Source Year Feb 2001 – Jan 2004, Data Extracted Feb 2004 2 AdvancePCS™, Dimension Rx, On-line, Feb 2002 to Jan 2004

4 4 Drug Use Trends in Outpatient Settings: Ciprofloxacin Ophthalmic Most common indication was “ conjunctivitis, other + unspecified. ” 1 Ciloxan was the most mentioned product for this indication in children 1-16 yrs. 1 1 IMS Health, National Disease and Therapeutic Index™, CD-ROM, Source Year Feb 2001 – Jan 2004, Data Extracted Feb 2004

5 5 Adverse Event Reports: Ciprofloxacin Ophthalmic 01/10/03 – 02/10/04 Total number of reports, all ages: –9 reports (3 U.S.) Age not specified for 2 Pediatric reports: –No pediatric reports were submitted during this time period.

6 6 Comments The FDA will continue its routine monitoring of adverse events in all populations.

7 7 One Year Post Exclusivity Adverse Event Review: Moxifloxacin Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004 J. Harry Gunkel, MD Medical Officer Division of Pediatric Drug Development Center for Drug Evaluation and Research Food and Drug Administration

8 8 Background Drug Information Moiety: Vigamox ® (moxifloxacin) Therapeutic Category: Ophthalmic anti-infective Sponsor: Alcon Laboratories, Inc. Indication: Adults and children ≥ 1 year: Treatment of bacterial conjunctivitis caused by susceptible organisms Original Market Approval: April 15, 2003 Pediatric Exclusivity Granted: January 10, 2003

9 9 Drug Use Trends in Outpatient Settings: Moxifloxacin Ophthalmic 800,000 prescriptions dispensed from Apr 2003 through Jan 2004. 1 26.2% of prescriptions were for children 1-16 years. 2 Ophthalmologists wrote most prescriptions (50.3%) from Feb 2003 – Jan 2004, followed by pediatricians (24%). 1 Most common indication was “ conjunctivitis, other + unspecified. ” 3 Vigamox accounted for 4.6% of the mentions for that indication in children 1-16 yrs. 3 1 IMS Health, National Prescription Audit Plus™, On-line, Source Year Feb 2001 – Jan 2004, Data Extracted Feb 2004 2 AdvancePCS™, Dimension Rx, On-line, Feb 2002 to Jan 2004 3 IMS Health, National Disease and Therapeutic Index™, CD-ROM, Source Year Feb 2001 – Jan 2004, Data Extracted Feb 2004

10 10 Adverse Event Reports: Moxifloxacin Ophthalmic 04/15/03 – 02/10/04 Total number of reports, all ages: – 1 report (U.S.) Pediatric reports: –1 report (U.S.) –Subconjunctival hemorrhage in 6.5 year old female 24 hours after use of Vigamox. Concomitant use of Augmentin. Recovery after discontinuation of Vigamox –Subconjunctival hemorrhage is a labeled adverse event in 1-6% of patients

11 11 Comments 1 labeled pediatric adverse event was reported The FDA will continue its routine monitoring of adverse events in all populations.

12 12 Clinical Study for Exclusivity StudyDesignPopulationEndpoints Moxifloxacin vs. Ciprofloxacin Multicenter, Randomized, Double-blind Neonates Clinical Cure Day 5 Microbial Eradication Rate

13 13 Clinical Study for Exclusivity: Results MoxifloxacinCiprofloxacinP-Value Clinical Cure 53%61% NS (Expected vehicle rate 70%)

Download ppt "1 One Year Post Exclusivity Adverse Event Review: Ciprofloxacin Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004."

Similar presentations

An Approach to Demonstration of Effectiveness

An Approach to Demonstration of Effectiveness
Dermatologic and Ophthalmic Drugs Advisory Committee July 12, 2004 1 Clinical Wrap-Up Denise Cook, M.D. Medical Officer Division of Dermatology and Dental.

Dermatologic and Ophthalmic Drugs Advisory Committee July 12, Clinical Wrap-Up Denise Cook, M.D. Medical Officer Division of Dermatology and Dental.
1 One Year Post Exclusivity Adverse Event Review: Fentanyl Transdermal System Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting.

1 One Year Post Exclusivity Adverse Event Review: Fentanyl Transdermal System Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting.
1 Drug Utilization for Immediate- and Modified Release Opioids in the U.S. Gianna C. Rigoni, Pharm.D., M.S. Epidemiologist Division of Surveillance, Research.

1 Drug Utilization for Immediate- and Modified Release Opioids in the U.S. Gianna C. Rigoni, Pharm.D., M.S. Epidemiologist Division of Surveillance, Research.
Special Topics in IND Regulation

Special Topics in IND Regulation
Office of Drug Evaluation IV, CDER FDA/IDSA/ISAP Workshop 4/16/04 Overview of PK-PD in Drug Development Programs: FDA Perspective FDA/IDSA/ISAP Workshop.

Office of Drug Evaluation IV, CDER FDA/IDSA/ISAP Workshop 4/16/04 Overview of PK-PD in Drug Development Programs: FDA Perspective FDA/IDSA/ISAP Workshop.
1 One Year Post Exclusivity Adverse Event Review: Atovaquone-Proguanil Pediatric Advisory Committee Meeting February 14, 2005 Alan M. Shapiro, MD, PhD,

1 One Year Post Exclusivity Adverse Event Review: Atovaquone-Proguanil Pediatric Advisory Committee Meeting February 14, 2005 Alan M. Shapiro, MD, PhD,
1 One Year Post-Exclusivity Adverse Event Review: Ertapenem Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.

1 One Year Post-Exclusivity Adverse Event Review: Ertapenem Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.
Prescription Drug Abuse Sharon Hertz, M.D. Medical Officer Division of Anesthetic, Critical Care and Addiction Drug Products Food and Drug Administration.

Prescription Drug Abuse Sharon Hertz, M.D. Medical Officer Division of Anesthetic, Critical Care and Addiction Drug Products Food and Drug Administration.
1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.

1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.
Coordinator University Clinical Research Pharmacy Investigational Drug Service (IDS) Marjorie Shaw Phillips, MS, RPh, FASHP Clinical Research Pharmacist.

Coordinator University Clinical Research Pharmacy Investigational Drug Service (IDS) Marjorie Shaw Phillips, MS, RPh, FASHP Clinical Research Pharmacist.
1 One Year Post Exclusivity Adverse Event Review as Mandated by the Best Pharmaceuticals for Children Act Presented at the Psychopharmacologic Drugs Advisory.

1 One Year Post Exclusivity Adverse Event Review as Mandated by the Best Pharmaceuticals for Children Act Presented at the Psychopharmacologic Drugs Advisory.
DSaRM Advisory Committee May 18, 2005 Active Surveillance for Drug Safety Signals: Past, Present, and Future Mary Willy, Ph.D. Division of Drug Risk Evaluation.

DSaRM Advisory Committee May 18, 2005 Active Surveillance for Drug Safety Signals: Past, Present, and Future Mary Willy, Ph.D. Division of Drug Risk Evaluation.
Supervised by : Dr. Adham Abutaha Presented by : Razan Abd Al-Nabi.

Supervised by : Dr. Adham Abutaha Presented by : Razan Abd Al-Nabi.
IDSA / ISAP / FDA Workshop on Antimicrobial Drug Development Update 2004 Edward Cox, MD MPH ODE IV Center for Drug Evaluation and Research US Food and.

IDSA / ISAP / FDA Workshop on Antimicrobial Drug Development Update 2004 Edward Cox, MD MPH ODE IV Center for Drug Evaluation and Research US Food and.
Yesterday, today, and tomorrow

Yesterday, today, and tomorrow
Center for Drug Evaluation and Research Patterns of Prescription Weight-Loss Drug Use Endocrinologic and Metabolic Drugs Advisory Committee Meeting Rockville,

Center for Drug Evaluation and Research Patterns of Prescription Weight-Loss Drug Use Endocrinologic and Metabolic Drugs Advisory Committee Meeting Rockville,
Adverse Event Tracking as mandated by the Best Pharmaceuticals for Children Act Dr. Solomon Iyasu Medical Team Leader Division of Pediatric Drug Development.

Adverse Event Tracking as mandated by the Best Pharmaceuticals for Children Act Dr. Solomon Iyasu Medical Team Leader Division of Pediatric Drug Development.
1 One Year Post Exclusivity Adverse Event Review: Ofloxacin Ophthalmic Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP.

1 One Year Post Exclusivity Adverse Event Review: Ofloxacin Ophthalmic Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP.
1 One Year Post Exclusivity Adverse Event Review: Alendronate Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP Medical.

1 One Year Post Exclusivity Adverse Event Review: Alendronate Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP Medical.

Similar presentations

Ads by Google